Recommended Treatment for Cutaneous Larva Migrans
For cutaneous larva migrans, treat with either ivermectin 200 μg/kg as a single oral dose OR albendazole 400 mg once daily for 3 days. 1
Treatment Algorithm
First-Line Options (Choose One):
- Ivermectin 200 μg/kg PO single dose (preferred by most recent guidelines)
- Albendazole 400 mg PO once daily for 3 days
Both regimens achieve comparable cure rates of approximately 88-89% 2, though the most recent 2025 UK guidelines list both as equivalent options 1.
Key Clinical Considerations:
Diagnosis is clinical - the characteristic intensely pruritic, serpiginous (snake-like), erythematous track migrating 1-2 cm per day is pathognomonic 1. The lesions most commonly affect the feet and lower extremities (77.6% of cases) 2.
Important contraindication: You must exclude Loa loa infection in patients who have traveled to endemic regions (Central/West Africa) BEFORE administering ivermectin, as treatment can precipitate severe reactions 1.
Management of Treatment Failure:
Approximately 13-16% of patients experience recurrence or persistent symptoms 2. In these cases:
- Re-treat with either ivermectin OR albendazole (whichever was not used initially)
- About 25% of patients require re-treatment 2
- Consider combination therapy with both albendazole AND ivermectin for refractory cases 3
Common Pitfalls to Avoid:
- Mebendazole is ineffective - showed 0% resolution rate in recent studies 2, despite being mentioned in older literature
- Topical treatments are less effective than oral antihelminthics 4
- Eosinophilia may be present but is not required for diagnosis 1
- The condition is self-limiting but causes significant pruritus and quality of life impairment, justifying treatment rather than observation 5
Geographic Context:
While traditionally considered a tropical disease, CLM is increasingly diagnosed in temperate regions. In the US, 69% of cases occur without international travel, predominantly in the southern states, with beach exposure and contact with pet dogs as primary risk factors 6.